Proteolytic activation defines distinct lymphangiogenic mechanisms for VEGFC and VEGFD

Hung M.  Bui; David  Enis; Marius R. Robciuc; Harri J. Nurmi; Jennifer  Cohen; Mei  Chen; Yiqing  Yang; Veerpal  Dhillon; Kathy  Johnson; Hong  Zhang; Robert  Kirkpatrick; Elizabeth  Traxler; Andrey Anisimov; Kari  Alitalo; Mark L.  Kahn

doi:10.1172/JCI83967

Proteolytic activation defines distinct lymphangiogenic mechanisms for VEGFC and VEGFD

Hung M. Bui, David Enis, Marius R. Robciuc, Harri J. Nurmi, Jennifer Cohen, Mei Chen, Yiqing Yang, Veerpal Dhillon, Kathy Johnson, Hong Zhang, Robert Kirkpatrick, Elizabeth Traxler, Andrey Anisimov, Kari Alitalo, Mark L. Kahn

Tutkimusohjelmayksikkö

Tutkimustuotos: Artikkelijulkaisu › Artikkeli › Tieteellinen › vertaisarvioitu

Alkuperäiskieli	englanti
Lehti	Journal of Clinical Investigation
Vuosikerta	126
Numero	6
Sivut	2167-2180
Sivumäärä	14
ISSN	0021-9738
DOI - pysyväislinkit	https://doi.org/10.1172/JCI83967
Tila	Julkaistu - 2016
OKM-julkaisutyyppi	A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä, vertaisarvioitu

Tieteenalat

3111 Biolääketieteet

Pääsy asiakirjaan

10.1172/JCI83967

Siteeraa tätä

Bui, H. M., Enis, D., Robciuc, M. R., Nurmi, H. J., Cohen, J., Chen, M., Yang, Y., Dhillon, V., Johnson, K., Zhang, H., Kirkpatrick, R., Traxler, E., Anisimov, A., Alitalo, K., & Kahn, M. L. (2016). Proteolytic activation defines distinct lymphangiogenic mechanisms for VEGFC and VEGFD. Journal of Clinical Investigation, 126(6), 2167-2180. https://doi.org/10.1172/JCI83967

@article{e0ec0a982dbe47e581f8be72755d8ac3,

title = "Proteolytic activation defines distinct lymphangiogenic mechanisms for VEGFC and VEGFD",

keywords = "3111 Biomedicine",

author = "Bui, {Hung M.} and David Enis and Robciuc, {Marius R.} and Nurmi, {Harri J.} and Jennifer Cohen and Mei Chen and Yiqing Yang and Veerpal Dhillon and Kathy Johnson and Hong Zhang and Robert Kirkpatrick and Elizabeth Traxler and Andrey Anisimov and Kari Alitalo and Kahn, {Mark L.}",

year = "2016",

doi = "10.1172/JCI83967",

language = "English",

volume = "126",

pages = "2167--2180",

journal = "Journal of Clinical Investigation",

issn = "0021-9738",

publisher = "AMERICAN SOCIETY FOR CLINICAL INVESTIGATION",

number = "6",

}

Bui, HM, Enis, D, Robciuc, MR , Nurmi, HJ, Cohen, J, Chen, M, Yang, Y, Dhillon, V, Johnson, K, Zhang, H, Kirkpatrick, R, Traxler, E, Anisimov, A , Alitalo, K & Kahn, ML 2016, 'Proteolytic activation defines distinct lymphangiogenic mechanisms for VEGFC and VEGFD', Journal of Clinical Investigation, Vuosikerta 126, Nro 6, Sivut 2167-2180. https://doi.org/10.1172/JCI83967

TY - JOUR

T1 - Proteolytic activation defines distinct lymphangiogenic mechanisms for VEGFC and VEGFD

AU - Bui, Hung M.

AU - Enis, David

AU - Robciuc, Marius R.

AU - Nurmi, Harri J.

AU - Cohen, Jennifer

AU - Chen, Mei

AU - Yang, Yiqing

AU - Dhillon, Veerpal

AU - Johnson, Kathy

AU - Zhang, Hong

AU - Kirkpatrick, Robert

AU - Traxler, Elizabeth

AU - Anisimov, Andrey

AU - Alitalo, Kari

AU - Kahn, Mark L.

PY - 2016

Y1 - 2016

KW - 3111 Biomedicine

U2 - 10.1172/JCI83967

DO - 10.1172/JCI83967

M3 - Article

SN - 0021-9738

VL - 126

SP - 2167

EP - 2180

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

IS - 6

ER -